HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.

AbstractPURPOSE:
To determine whether a three-year fluocinolone acetonide sustained drug delivery system can be implanted safely at the same time that phacoemulsification and intraocular lens (IOL) implantation are performed for a visually significant cataract in eyes with uveitis.
DESIGN:
Retrospective, single-center case series.
METHODS:
All consecutive patients treated from April 1998 through September 2006 at an academic clinical practice with intermediate uveitis, posterior uveitis, or panuveitis requiring immunosuppressive therapy, periocular corticosteroid injections, or both. Phacoemulsification, IOL implantation, and fluocinolone acetonide implant insertion were performed during a single surgical session. The main outcome measures were preoperative and postoperative ocular inflammation, visual acuity (VA), intraoperative complications, anti-inflammatory medication use, IOP, and postoperative adverse events.
RESULTS:
Twenty-four eyes of 21 patients were studied. Mean follow-up duration was 27 months (range, six to 60 months). No patients had intraoperative complications. The mean Snellen VA at baseline was 20/316, which improved significantly to 20/75 at 12 months. The average number of recurrences in the 12 months before implantation was 2.2 episodes per eye. Only one eye experienced a recurrence at seven months after implantation. Topical corticosteroids, posterior sub-Tenon capsule injections, and systemic anti-inflammatory medications were reduced significantly at 12 months. Average IOP was unchanged after surgery compared with preoperative IOP; 15% underwent glaucoma filtering surgery.
CONCLUSIONS:
A fluocinolone acetonide implant insertion can be combined safely with phacoemulsification plus IOL implantation during the same surgical session in eyes with uveitis. VA generally was improved, uveitis recurrences decreased, and the need for immunosuppression decreased. The most common side effect was increased IOP.
AuthorsJanet J Chieh, Alan N Carlson, Glenn J Jaffe
JournalAmerican journal of ophthalmology (Am J Ophthalmol) Vol. 146 Issue 4 Pg. 589-594 (Oct 2008) ISSN: 1879-1891 [Electronic] United States
PMID18639220 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Drug Implants
  • Glucocorticoids
  • Fluocinolone Acetonide
Topics
  • Adolescent
  • Adult
  • Aged
  • Cataract (complications)
  • Delayed-Action Preparations
  • Drug Implants
  • Female
  • Fluocinolone Acetonide (administration & dosage, adverse effects)
  • Follow-Up Studies
  • Glucocorticoids (administration & dosage, adverse effects)
  • Humans
  • Intraocular Pressure
  • Intraoperative Complications
  • Lens Implantation, Intraocular
  • Male
  • Middle Aged
  • Phacoemulsification
  • Postoperative Complications
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Uveitis (complications, drug therapy)
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: